Abstract
Introduction: Recently, enzalutamide, apalutamide, and darolutamide have shown benefits in metastasis-free survival in non-metastatic castration-resistant prostate cancer (nmCRPC) patients compared to placebo. Previous evidence about the safety profile of these new androgens is limited. This meta-analysis studies seizure and neuropsychiatric effects of new anti-androgens compared to placebo in nmCRPC patients. Methods: PubMed and Cochrane databases were systematically reviewed until 1 March 2020 by 2 independent researchers using a pre-specified search strategy. Placebo-compared randomized controlled trials (RCTs) of nmCRPC patients treated with new anti-androgens providing data on neuropsychiatric events and seizures were included. Variables were seizure, headache, mental impairment, and dizziness. Pooled risk ratios (RR) were calculated using the Mantel-Hansel random effects model and Review Manager v5.3 software. Results: After systematic review, 3 eligible RCTs were selected that included 4,104 patients; 2,687 comprised the treatment group and 1,417 the control group. No significant increase in RR for seizures was registered with the new anti-androgens compared to placebo (RR 1.96; 95% confidence interval [CI] 0.40–9.61). However, 2 trials excluded patients with risk factors or a history of seizures. There was also no significant increase RR for grade ≥3 seizures (RR 2.50; 95% CI 0.12–52.02). RR for suffering dizziness (any grade) was 1.57 (95% CI 1.07–2.32) with the new anti-androgens, but no significant differences were found in the other study regarding neuropsychiatric events or grade ≥3 events. Conclusions: New anti-androgens (i.e., enzalutamide, apalutamide, and darolutamide) are acceptably safe in terms of seizures and neuropsychiatric toxicity compared to placebo in patients with nmCRPC.
Journal Section:
Meta-Analysis
References
1.
Cornford
P
, Bellmunt
J
, Bolla
M
, Briers
E
, De Santis
M
, Gross
T
, et al.. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
. Eur Urol
. 2017
Apr
;71
(4
):630
–42
.
[PubMed]
0302-28382.
Scher
HI
, Sawyers
CL
. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis
. J Clin Oncol
. 2005
Nov
;23
(32
):8253
–61
.
[PubMed]
0732-183X3.
Tannock
IF
, de Wit
R
, Berry
WR
, Horti
J
, Pluzanska
A
, Chi
KN
, et al.; TAX 327 Investigators
. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
. N Engl J Med
. 2004
Oct
;351
(15
):1502
–12
.
[PubMed]
0028-47934.
de Bono
JS
, Oudard
S
, Ozguroglu
M
, Hansen
S
, Machiels
JP
, Kocak
I
, et al.; TROPIC Investigators
. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
. Lancet
. 2010
Oct
;376
(9747
):1147
–54
.
[PubMed]
0140-67365.
Kantoff
PW
, Higano
CS
, Shore
ND
, Berger
ER
, Small
EJ
, Penson
DF
, et al.; IMPACT Study Investigators
. Sipuleucel-T immunotherapy for castration-resistant prostate cancer
. N Engl J Med
. 2010
Jul
;363
(5
):411
–22
.
[PubMed]
0028-47936.
Parker
C
, Nilsson
S
, Heinrich
D
, Helle
SI
, O’Sullivan
JM
, Fosså
SD
, et al.; ALSYMPCA Investigators
. Alpha emitter radium-223 and survival in metastatic prostate cancer
. N Engl J Med
. 2013
Jul
;369
(3
):213
–23
.
[PubMed]
0028-47937.
Fizazi
K
, Scher
HI
, Molina
A
, Logothetis
CJ
, Chi
KN
, Jones
RJ
, et al.; COU-AA-301 Investigators
. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
. Lancet Oncol
. 2012
Oct
;13
(10
):983
–92
.
[PubMed]
1470-20458.
Beer
TM
, Armstrong
AJ
, Rathkopf
D
, Loriot
Y
, Sternberg
CN
, Higano
CS
, et al.. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
. Eur Urol
. 2017
Feb
;71
(2
):151
–4
.
[PubMed]
0302-28389.
Hussain
M
, Fizazi
K
, Saad
F
, Rathenborg
P
, Shore
N
, Ferreira
U
, et al.. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
. N Engl J Med
. 2018
Jun
;378
(26
):2465
–74
.
[PubMed]
0028-479310.
Smith
MR
, Saad
F
, Chowdhury
S
, Oudard
S
, Hadaschik
BA
, Graff
JN
, et al.; SPARTAN Investigators
. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
. N Engl J Med
. 2018
Apr
;378
(15
):1408
–18
.
[PubMed]
0028-479311.
Fizazi
K
, Shore
N
, Tammela
TL
, Ulys
A
, Vjaters
E
, Polyakov
S
, et al.; ARAMIS Investigators
. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
. N Engl J Med
. 2019
Mar
;380
(13
):1235
–46
.
[PubMed]
0028-479312.
Small
EJ
, Saad
F
, Chowdhury
S
, Oudard
S
, Hadaschik
BA
, Graff
JN
, et al.. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
. Ann Oncol
. 2019
Nov
;30
(11
):1813
–20
.
[PubMed]
0923-753413.
Cora
N.
Sternberg, Karim Fizazi, et al. Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). J. Clin. Oncol. 2020
38:15_suppl, 5515-5515.14.
Fizazi
K
, Shore
ND
, Tammela
T
, Ulys
A
, Vjaters
E
, Polyakov
S
, et al.. Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC)
. J Clin Oncol
. 2020
;38
(15
):5514
–5514
. 0732-183X15.
Slovin
S
, Clark
W
, Carles
J
, Krivoshik
A
, Park
JW
, Wang
F
, et al.. Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: the UPWARD Study
. JAMA Oncol
. 2018
May
;4
(5
):702
–6
.
[PubMed]
2374-243716.
Gillessen
S
, Attard
G
, Beer
TM
, Beltran
H
, Bossi
A
, Bristow
R
, et al.. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
. Eur Urol
. 2018
Feb
;73
(2
):178
–211
.
[PubMed]
0302-283817.
Pilon
D
, Behl
AS
, Ellis
LA
, Robitaille
MN
, Lefebvre
P
, Dawson
NA
. Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy
. Am Health Drug Benefits
. 2017
May
;10
(3
):143
–53
.
[PubMed]
1942-296218.
Liberati
A
, Altman
DG
, Tetzlaff
J
, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLOS Med. 2009
;6(7):e1000100. Cochrane Handbook for Systematic Reviews of Interventions. [Internet]. [cited 2021 Jan 6]. Available from: https://training.cochrane.org/handbook/current/chapter-0819.
Cochrane Handbook for Systematic Reviews of Interventions. [Internet]. [cited 2021 Jan 6]. Available from: https://training.cochrane.org/handbook/current/chapter-08.
20.
Drago
JZ
, Gönen
M
, Thanarajasingam
G
, Sacks
CA
, Morris
MJ
, Kantoff
PW
, et al. Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer. J Natl Cancer Inst. 2020
;28:djaa134. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. [cited 18 april 2020]. Available in: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_4021.
Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. [cited 18 april 2020]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
22.
Roviello
G
, Gatta Michelet
MR
, D’Angelo
A
, Nobili
S
, Mini
E
. Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials
. Clin Transl Oncol
. 2020
Jul
;22
(7
):1033
–9
.
[PubMed]
1699-048X23.
Roviello
G
, Sigala
S
, Sandhu
S
, Bonetta
A
, Cappelletti
MR
, Zanotti
L
, et al.. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials
. Eur J Cancer
. 2016
Jul
;61
:111
–21
.
[PubMed]
0959-804924.
Foster
WR
, Car
BD
, Shi
H
, Levesque
PC
, Obermeier
MT
, Gan
J
, et al.. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
. Prostate
. 2011
Apr
;71
(5
):480
–8
.
[PubMed]
0270-413725.
Scher
HI
, Beer
TM
, Higano
CS
, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010
;375(9724):1437-46. 926.
Dharmani
C
, Bonafede
M
, Krivoshik
A
. Risk Factors for and Incidence of Seizures in Metastatic Castration-Resistant Prostate Cancer: A Real-World Retrospective Cohort Study
. Clin Drug Investig
. 2017
Dec
;37
(12
):1183
–90
.
[PubMed]
1173-256327.
Smith
MR
, Antonarakis
ES
, Ryan
CJ
, Berry
WR
, Shore
ND
, Liu
G
, et al.. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
. Eur Urol
. 2016
Dec
;70
(6
):963
–70
.
[PubMed]
0302-283828.
Moilanen
AM
, Riikonen
R
, Oksala
R
, Ravanti
L
, Aho
E
, Wohlfahrt
G
, et al.. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
. Sci Rep
. 2015
Jul
;5
(1
):12007
.
[PubMed]
2045-232229.
Zurth
C
, Sandmann
S
, Trummel
D
, Seidel
D
, Gieschen
H
. Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography
. J Clin Oncol
. 2018
;36
6_suppl
:345
–345
. 0732-183X30.
Fizazi
K
, Massard
C
, Bono
P
, Jones
R
, Kataja
V
, James
N
, et al.; ARADES study group
. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
. Lancet Oncol
. 2014
Aug
;15
(9
):975
–85
.
[PubMed]
1470-204531.
Liu
Z
, Zhang
T
, Ma
Z
, Zheng
S
, Chen
J
, Wu
Z
, et al.. Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis
. Am J Clin Oncol
. 2020
Apr
;43
(4
):288
–97
.
[PubMed]
0277-3732© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2021
You do not currently have access to this content.
